- ￥2009
- BioLegend
- 116519
- 美国
- 2025年07月16日
- 免疫荧光，流式
- 小鼠
- 小鼠
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
PE/Cyanine7 anti-mouse H-2Kb
- 抗体英文名：
PE/Cyanine7 anti-mouse H-2Kb
- 浓度：
0.2 mg/ml
- 应用范围：
免疫荧光，流式
- 宿主：
小鼠
- 供应商：
上海善然生物
- 库存：
现货
- 抗原来源：
小鼠
- 保质期：
2-3年左右
- 适应物种：
小鼠
- 标记物：
PE/Cyanine7
- 克隆性：
单克隆
- 保存条件：
2-8度
- 形态：
液体
- 规格：
25ug
PE/Cyanine7 anti-mouse H-2K Antibody
b
AF6-88.5
Catalog# / Size 116519 / 25 µg
116520 / 100 µg
Clone
Regulatory Status RUO
Other Names MHC class I
Isotype Mouse (BALB/c) IgG2a, κ
Description The AF6-88.5 antibody reacts with H-2K MHC class I alloantigen expressed on nucleated
cells from mice of the H-2K haplotype. H-2K is involved in antigen presentation to T cells
expressing CD3/TCR and CD8 proteins. The AF6-88.5 antibody does not cross-react with
other haplotypes (d, f, j, k, p, q, r, s, u, v).
b
b b
Product Details
Verified Reactivity Mouse
Antibody Type Monoclonal
Host Species Mouse
Immunogen C57BL mouse splenocytes
Formulation Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under
optimal conditions.
Concentration 0.2 mg/ml
Storage & Handling The antibody solution should be stored undiluted between 2°C and 8°C, and protected from
prolonged exposure to light. Do not freeze
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验更多产品详细信息欢迎来电咨询~周祥15900853496（微信同号)，汪海洋15901695283(微信同号)
Anti-Factor H Autoantibodies Assay
of autoantibodies directed against Factor H (FH), the main plasmatic alternative complement pathway regulatory protein. Their presence induces an acquired functional FH deficiency. The anti-FH autoantibodies screening must be performed at the very onset
Adenoviral-Mediated Anti-H-ras Ribozyme for the Treatment of Bladder Cancer
Bladder cancer is the fifth most common malignancy, demonstrated by the approx 52,900 patients that will be diagnosed in the United States in 1996 (1 ). Around 15–20% of these patients will be characterized by muscle invasion or node posmve
Tissue-Specific Delivery of an anti-H-ras Ribozyme Against Malignant Melanoma
Malignant melanoma is an increasingly important clinical problem in the United States, because the incidence of cutaneous malignant melanoma has been increasing significantly in recent years (1 ,2 ) Despite the use of cancer chemotherapy
技术资料暂无技术资料 索取技术资料
